346 related articles for article (PubMed ID: 32495677)
21. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study.
Sanghai S; Wong C; Wang Z; Clive P; Tran W; Waring M; Goldberg R; Hayward R; Saczynski JS; McManus DD
J Am Heart Assoc; 2020 Mar; 9(6):e014108. PubMed ID: 32146898
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
[TBL] [Abstract][Full Text] [Related]
23. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS; Lip GY
Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
[TBL] [Abstract][Full Text] [Related]
24. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.
Chan YH; Lee HF; Li PR; Liu JR; Chao TF; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2020 May; 19(1):63. PubMed ID: 32404168
[TBL] [Abstract][Full Text] [Related]
26. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
van den Dries CJ; Pajouheshnia R; van den Ham HA; Souverein P; Moons KGM; Hoes AW; Geersing GJ; van Doorn S
Br J Clin Pharmacol; 2023 Feb; 89(2):751-761. PubMed ID: 36102068
[TBL] [Abstract][Full Text] [Related]
27. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
28. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry.
Murata N; Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itoh S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Circ J; 2019 Mar; 83(4):727-735. PubMed ID: 30726797
[TBL] [Abstract][Full Text] [Related]
30. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
31. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
33. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use.
Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005894. PubMed ID: 32160790
[TBL] [Abstract][Full Text] [Related]
35. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
36. Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation.
Sugrue A; Sanborn D; Amin M; Farwati M; Sridhar H; Ahmed A; Mehta R; Siontis KC; Mulpuru SK; Deshmukh AJ; Gersh BJ; Asirvatham SJ; Madhavan M
Am J Cardiol; 2021 Apr; 144():52-59. PubMed ID: 33385355
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes of Off-Label Underdosing of Direct Oral Anticoagulants After Ablation for Atrial Fibrillation.
Wakamatsu Y; Nagashima K; Watanabe R; Arai M; Yokoyama K; Matsumoto N; Otsuka T; Suzuki S; Hirata A; Murakami M; Takami M; Kimura M; Fukaya H; Nakahara S; Kato T; Hayashi H; Iwasaki YK; Shimizu W; Nakajima I; Harada T; Koyama J; Okumura K; Tokuda M; Yamane T; Tanimoto K; Momiyama Y; Nonoguchi N; Soejima K; Ejima K; Hagiwara N; Harada M; Sonoda K; Inoue M; Kumagai K; Hayashi H; Yazaki Y; Satomi K; Watari Y; Okumura Y
Int Heart J; 2020 Nov; 61(6):1165-1173. PubMed ID: 33191353
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
[TBL] [Abstract][Full Text] [Related]
40. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
